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Introduction {#sec1}
============

Congenital heart disease affects up to 1% of all live births in the west and constitutes a major public health burden ([@bib25]). Numerous transcription factors have been shown to play a decisive role in vertebrate heart formation (reviewed in [@bib9]). Identifying the targets of these factors and their regulatory interactions will be a major step toward understanding the broader cardiac developmental program. NKX2-5 is one of the earliest transcription factors expressed in the cardiac lineage, and genetic studies have demonstrated that, from flies to man, the protein has an essential function in heart development ([@bib5; @bib47]). For example, NKX2-5 has been shown to regulate the size and proliferation of cardiac precursor populations, terminal differentiation of the myocardium, establishment of the ventricular conduction system, and postnatal conduction function ([@bib8; @bib28; @bib40]). In humans, mutations in the *NKX2-5* gene cause congenital heart disease; haploinsufficiency results in a spectrum of congenital heart disease of varying phenotypic penetrance, which is mirrored in mouse models (reviewed in [@bib1]).

Genome-wide occupancy profiling using chromatin immunoprecipitation (ChIP) recently has been used to identify NKX2-5-binding sites in both cultured cell lines and adult heart ([@bib22; @bib49]); but, despite the evident importance of NKX2-5 in heart development, no comparable studies have addressed its place within the gene regulatory network that drives cardiogenesis.

Here, we have combined genome-wide ChIP followed by massively parallel DNA sequencing (ChIP-seq) and whole-transcriptome RNA sequencing (RNA-seq) using embryonic hearts from a mouse line that shows hypomorphic expression of NKX2-5 and models human cardiomyopathy. This has enabled us to identify direct targets of the NKX2-5 transcription factor during heart development in vivo. We have found that a large proportion of cardiac enhancers binding NKX2-5 have an overlapping binding site for the homeobox transcription factor, MEIS1, indicating a regulatory interaction between these two proteins. Our data suggest that the combination of shared transcriptional targets, differential DNA-binding affinities, and overlapping expression domains provides a mechanism for spatial and temporal synchronization of a common pool of targets between NKX2-5 and MEIS1.

Results {#sec2}
=======

ChIP-Seq Analysis in the Embryonic Heart Identifies Putative Direct Targets of NKX2-5 with a Critical Role in Heart Structure and Function {#sec2.1}
------------------------------------------------------------------------------------------------------------------------------------------

We performed ChIP with embryonic day (E)11.5 mouse embryo hearts using an NKX2-5 antibody followed by massive, parallel sequencing (ChIP-seq) to identify 2,610 regions enriched for that factor ([Data S1](#mmc2){ref-type="supplementary-material"}). Of these, 28 were randomly selected for individual validation by ChIP-qPCR, all showing consistent enrichment for NKX2-5 binding in vivo ([Figure S1](#mmc1){ref-type="supplementary-material"}).

Bioinformatic analysis identified 3,313 genes flanking the NKX2-5-binding loci (the two nearest genes for each region enriched in a maximum distance of 1 Mb were considered), and we performed a computational analysis for enrichment of gene ontology (GO) terms associated with those genes. This identified significant enrichment of biological process related to muscle structure development and cardiac chamber development ([Figure 1](#fig1){ref-type="fig"}A), in agreement with the known role of NKX2-5 as a cardiac transcription factor.

To assess whether the NKX2-5-binding loci are likely to identify transcriptional enhancer regions, we compared them with those enriched for binding of P300 in the heart at the same stage ([@bib6]). P300 is a known marker of enhancer regions and its binding shows a significant overlap with the NKX2-5 ChIP-seq loci (78.4-fold enrichment compared to random regions; see [Table S1](#mmc1){ref-type="supplementary-material"}). Furthermore, by comparing both NKX2-5 and P300 datasets with regions tested for enhancer activity in transgenic mice (as compiled in the Vista enhancer database \[[@bib50]\]), we found that binding of NKX2-5 was even more reliable for predicting cardiac enhancer activity in the E11.5 mouse heart than binding of P300 (83% versus 58%, respectively; [Figure 1](#fig1){ref-type="fig"}B). Our data also show significant overlap with recent studies of cardiac transcription factor binding that have used adult heart or cardiac HL-1 cells ([@bib6; @bib22; @bib43; @bib49]; [Table S1](#mmc1){ref-type="supplementary-material"}).

Only a small proportion of putative targets have been the subject of published studies using gene ablation that could reveal cardiac defects. However, several already have been constitutively targeted as part of the EUCOMM/KOMP initiative ([@bib7]) and subject to comprehensive imaging at E14.5 (<http://dmdd.org.uk>; [@bib34]). Six of the eight genes studied in this way and present in our list of targets show clear cardiac developmental defects, consistent with a role in cardiogenesis. All show large ventricular septal defects associated with aberrant connection of the great vessels to the heart chambers (either overriding aorta \[OA\] or double outlet right ventricle \[DORV\]). Several show abnormally thin ventricular walls coupled with an increase in the ventricular trabecular network ([Data S2](#mmc3){ref-type="supplementary-material"}). Furthermore, selected NKX2-5-binding sites conferred cardiac expression in a transgenic reporter assay with zebrafish embryos ([Figure S2](#mmc1){ref-type="supplementary-material"}), confirming their ability to act as cardiac enhancers. Taken together with the bioinformatics data, these results indicate that a large proportion of the NKX2-5-binding regions in the embryonic heart that we have identified are likely to be functionally relevant and associated with cardiac development or function in vivo.

Identification of an Overlapping Binding Site Shared by NKX2-5 and MEIS1 {#sec2.2}
------------------------------------------------------------------------

Sequence analysis of the 25 bp flanking the summit of each NKX2-5-binding region was undertaken, using a de novo motif-binding program to identify conserved DNA motifs. As expected, the most common of these was a consensus NKX2-5-binding site (hereafter termed "selex"; [Figure 1](#fig1){ref-type="fig"}C, e value = 1.6e−24), which matched that previously established for the protein (NKX2-5_3436.1, uniprobe, UP00249, p = 4.71375e−6) as well as the NKX2-5-binding motifs identified in recent ChIP-seq studies with adult heart and HL-1 cells ([@bib22; @bib49]; [Figure S3](#mmc1){ref-type="supplementary-material"}).

Surprisingly, the de novo motif-binding program also identified a second common consensus (hereafter termed "de novo"; [Figure 1](#fig1){ref-type="fig"}C, e value = 6.5e−95) that appears to be a hybrid site: its 3′ portion matches a binding motif previously identified for the homeodomain protein MEIS1 (MEIS1_2335.1, uniprobe, UP00186, p = 0.000185), while the 5′ is similar to the selex (NKX2-5)-binding motif. The hybrid, de novo motif, therefore, appears to comprise an overlapping binding site for the two transcription factors. Using the Find Individual Motif Occurrences (FIMO) software package to analyze regions immediately encompassing the summit of NKX2-5 binding (±25 bp), we found that the de novo motif is present in 53.4% of binding regions, compared with 42% for the selex motif. Only 4.6% of the regions analyzed contained both the de novo and selex consensus sequences. These data suggest that, in vivo, a significant proportion of NKX2-5 binding on cardiac enhancers occurs via an overlapping site shared with MEIS1.

To test the possible biological relevance of a binding site shared by NKX2-5 and MEIS1, we first re-assessed the relative expression patterns of the two transcription factors in the early embryo. At E8.5 *Nkx2*-*5* is strongly expressed in the cardiac tube, with weaker expression in the adjacent anterior heart field (AHF) ([Figure 2](#fig2){ref-type="fig"}A, black arrowhead and white arrow, respectively). At the same stage, although *Meis1* expression is undetectable in much of the heart tube, it is strongly expressed in both the AHF and in the distal part of the outflow tract (OFT), overlapping at this stage with the expression domain of *Nkx2*-*5*. At E9.5, expression of both *Nkx2*-*5* and *Meis1* persists strongly in the AHF while levels of *Meis1* in the distal OFT are reduced ([Figure 2](#fig2){ref-type="fig"}A). Coexpression of MEIS1 and NKX2-5 within the distal OFT of the heart tube at E8.5 was confirmed by immunohistochemistry ([Figure 2](#fig2){ref-type="fig"}B).

Using electrophoretic mobility shift assays (EMSAs), we confirmed that both proteins can indeed bind in vitro to the de novo motif identified from ChIP-seq ([Figure 3](#fig3){ref-type="fig"}A; [Figure S3](#mmc1){ref-type="supplementary-material"}B). By comparing the effectiveness of the de novo and selex sequences to compete for binding, we established that NKX2-5 has a much higher affinity for the selex sequence compared with the de novo motif ([Figure 3](#fig3){ref-type="fig"}B). Moreover, when tested together, we could find no evidence for simultaneous binding of both proteins to the de novo sequence, rather each apparently bound independently ([Figure 3](#fig3){ref-type="fig"}C, arrow and arrowhead). Titration experiments demonstrated that even increasing the amount of either protein failed to produce an additional larger-sized complex ([Figure 3](#fig3){ref-type="fig"}C). Indeed, at higher concentrations of MEIS1 protein, NKX2-5 binding disappeared, ([Figure 3](#fig3){ref-type="fig"}C, compare lane 3 to lanes 10 and 11, red arrows). Interestingly, at higher NKX2-5 doses, although MEIS1 binding was inhibited, there was not the expected further increase in NKX2-5 binding. One possible explanation for this behavior is that, at higher concentrations, NKX2-5 may sequester MEIS1 in a direct complex that can bind neither site.

Our EMSA results indicate that binding of NKX2-5 and MEIS1 on the de novo motif is mutually exclusive. Consistent with this, in a luciferase assay, individually both NKX2-5 and MEIS1 were able to transactivate reporter expression via the de novo sequence, but we found no evidence of synergistic activation by the two factors ([Figure 3](#fig3){ref-type="fig"}D).

MEIS1 and NKX2-5 Successively Bind to a Popdc2 Enhancer {#sec2.3}
-------------------------------------------------------

The Popdc2 gene (1 kb; [Figure 4](#fig4){ref-type="fig"}A, black bar) acts as an enhancer, driving cardiac expression of a fluorescent reporter in transgenic fish ([Figure S2](#mmc1){ref-type="supplementary-material"}). A de novo DNA-binding site was found in the region enriched for NKX2-5 binding, 110 bp upstream of the Popdc2 transcription start site ([Figure 4](#fig4){ref-type="fig"}A). The same region also was found to be enriched for MEIS binding within the first branchial arch of the early embryo ([@bib3] and see below). This sequence also drives cardiac expression in the developing mouse heart ([Figure 4](#fig4){ref-type="fig"}B). Analysis of representative transient transgenic embryos at E9.5 showed that the enhancer-driven transgene recapitulated normal expression in differentiated cardiomyocytes of the cardiac tube and cardiac precursors lying in the AHF ([@bib19]). Expression of the transgene also was observed in the pharyngeal arch and the proepicardium ([Figure 4](#fig4){ref-type="fig"}B, asterisk and white arrow), as observed for the *Popdc2* gene itself ([@bib19]). *Meis1* expression also was observed in these tissues, but no expression of *Nkx2*-*5* could be detected (data not shown). Moreover, *Popdc2* RNA expression was downregulated in Nkx2-5-null hearts at E9.0 compared with controls ([Figure S4](#mmc1){ref-type="supplementary-material"}A). A similar, though less profound effect was observed at E11.5 in hearts that are hypomorphic for NKX2-5 expression ([Figure S4](#mmc1){ref-type="supplementary-material"}B). These data indicate that NKX2-5 plays a major role in regulating the expression of *Popdc2*.

To examine directly the relative binding of MEIS1 and NKX2-5 in vivo, we performed ChIP experiments on the Popdc2 enhancer using chromatin from samples prepared from the AHF and heart of E9.5 embryos. NKX2-5 binding on the Popdc2 enhancer was found to be much stronger in chromatin extracted from the embryonic heart compared to the adjacent AHF ([Figure 4](#fig4){ref-type="fig"}C). Conversely, MEIS1 bound more strongly in chromatin extracted from the AHF rather than the heart. The relatively low level of enrichment found for MEIS1 in the heart and NKX2-5 in the AHF parallels the low level of expression of these factors within the respective tissues ([Figure 2](#fig2){ref-type="fig"}). These results indicate that MEIS1 binding on the *Popdc2* enhancer predominates in the AHF, while NKX2-5 binding predominates in the heart.

To assess whether other gene enhancers containing the de novo DNA-binding motif showed similar tissue-specific differential binding, we tested four such genomic enhancer regions identified by ChIP-seq for Nkx2-5 in the embryonic heart (Myocardin, Lpar3, Cadm1, and Gja1/Hsf2 loci; [Data S3](#mmc1){ref-type="supplementary-material"}). All showed a pattern of enrichment for MEIS binding in the AHF and NKX2-5 binding in the heart, suggesting that this behavior is likely to be shared by many of the genomic regions harboring the de novo site identified by our ChIP-seq study.

MEIS1 and NKX2-5 Bind to the Same Regions In Vivo {#sec2.4}
-------------------------------------------------

It is well established that the mesodermal core of the first and second branchial arches contains cardiac progenitor cells, which migrate from this region to populate the OFT and chambers of the developing heart ([@bib31]). A recent study has documented MEIS genomic occupancy in the branchial arches ([@bib3]), enabling us to compare on a genome-wide basis the loci binding MEIS in the AHF with those binding Nkx2-5 in the heart.

Strikingly, 765 of the 2,610 regions enriched for NKX2-5 binding (29.31%) also were identified by MEIS binding in the first branchial arches. A similar overlap was evident with the second branchial arches (787 regions or 30.15%; [Table S1](#mmc1){ref-type="supplementary-material"}; [Figure 4](#fig4){ref-type="fig"}D). This represents a 50-fold enrichment compared to random ([Table S1](#mmc1){ref-type="supplementary-material"}), lending further support to the suggestion that the successive binding of MEIS and NKX2-5 that we initially observed for *Popdc2* is shared by an entire subset of cardiac enhancers.

In an attempt to discriminate between the occurrence of closely associated and directly overlapping binding sites for MEIS1 and NKX2-5, we repeated this analysis but restricted the comparison to a region of ±6 bp around the summit of the binding peaks identified in the different datasets. Under these conditions, 105 binding sites overlapped between NKX2-5 and MEIS in the first branchial arch and, therefore, most likely represent direct overlap of the two binding sites. Comparable analysis yielded 79 common, overlapping sites in the second branchial arch. These results suggest that a significant fraction of MEIS and NKX2-5 interaction in vivo is mediated by a direct site overlap.

Interestingly, GO analysis suggests that the subset of genes regulated by both MEIS1 and NKX2-5 may have a distinct function. The 1,845 regions that bound NKX2-5 alone are associated with genes involved with cardiac muscle structure and development; in contrast, the 765 regions that bound both MEIS1 and NKX2-5 are primarily associated with genes involved with DNA metabolic processes, signaling, and cell-cycle regulation ([Figure 4](#fig4){ref-type="fig"}E). No significant difference was evident in GO terms when we divided the 765 between those showing the closest association of MEIS and NKX2-5 binding (105) and the rest (660).

Identification of Putative Direct Targets for NKX2-5 Reveals a Dual Role as Both Activator and Repressor {#sec2.5}
--------------------------------------------------------------------------------------------------------

Comparison of ChIP-seq and transcriptomic data provides a powerful way to identify likely transcriptional targets by identifying those that both bind the transcription factor and are dysregulated in its absence ([@bib42]). For NKX2-5, this strategy is precluded since *Nkx2*-*5* knockout embryos die early (E9.5) due to failure of heart development ([@bib5; @bib47]). As an alternative, we took advantage of a previously generated mouse model showing hypomorphic expression of NKX2-5 ([@bib40; @bib46]), enabling us to test the effect of reduction, rather than absence, of NKX2-5 expression. Mendelian analysis showed no change in mortality of this hypomorphic line at E11.5, E12.5, and E13.5. However, by E14.5, only 60% of the expected number of hypomorphic embryos were recovered ([Table S2](#mmc1){ref-type="supplementary-material"}) and only a few hypomorphic embryos were obtained at birth (none surviving past weaning). Consistent with these observations, the structure of the hypomorph heart showed profound abnormalities by E14.5, including thinning of ventricular walls, the presence of large ventricular septal defects, and signs of hypertrabeculation ([Figure 5](#fig5){ref-type="fig"}A).

In contrast, at E11.5, the hearts of hypomorphic embryos were morphologically indistinguishable from those of sibling controls, and we therefore used this stage for transcriptome analysis. RNA-seq comparing E11.5 hypomorphic mutant and control hearts identified statistically significant alterations in the expression of 1,492 genes ([Data S4](#mmc5){ref-type="supplementary-material"}). By using this to filter the ChIP-seq data, we were able to identify 309 genes as high-probability, direct targets of NKX2-5 ([Figure 5](#fig5){ref-type="fig"}B). GO term analysis of these indicated that the categories of biological process most enriched are related to cell signaling and differentiation ([Figure 5](#fig5){ref-type="fig"}C, p \< 0.002 for all categories). Furthermore, the most enriched biological pathways are related to signaling ([Figure S4](#mmc1){ref-type="supplementary-material"}D). Interestingly, of the 309 identified genes, 172 (55.6%) were downregulated and 137 (44.4%) were upregulated, suggesting that NKX2-5 functions both as a transcriptional activator and as a repressor ([Figure 5](#fig5){ref-type="fig"}B).

One role of NKX2-5 suggested by studies of the null mutant is in the regulation of cardiac chamber development ([@bib16; @bib47]). We tested this hypothesis by classifying the direct NKX2-5 targets identified in our studies according to their expression pattern in the hypomorphic heart, taking advantage of previous studies that examined genes differentially expressed between chamber and non-chamber myocardium at E10.5 ([@bib26]). This enabled us to distinguish between genes restricted to the atrioventricular canal (AVC) or working myocardium, compared with those more broadly expressed (and classified as "pan-myocardial"). Those expressed in the AVC or throughout the myocardium were upregulated or downregulated in the hypomorph in approximately equal proportions ([Figure 5](#fig5){ref-type="fig"}D). In contrast, those NKX2-5 targets whose expression was restricted to the chamber myocardium were predominantly downregulated in the mutant ([Figure 5](#fig5){ref-type="fig"}D), consistent with an essential role for NKX2-5 in promoting cardiac chamber formation.

NKX2-5 Directly Represses the Expression of Tnnt3 and Tnni2 in the Atria {#sec2.6}
------------------------------------------------------------------------

Our finding that almost half of the putative direct targets of NKX2-5 identified by intersection of ChIP-seq and transcriptomic data are upregulated in the hypomorph is striking, since most previous studies have focused on the role of NKX2-5 as a transcriptional activator ([@bib47]). One noteworthy example of negative regulation revealed by our study is associated with binding of NKX2-5 to a region 1 kb upstream of the Lsp1 gene transcription start site ([Figure 6](#fig6){ref-type="fig"}A) harboring a selex DNA-binding site (referred as Tnni2-Tnnt3-enh). Lsp1 showed no detectable expression in cardiomyocytes at E11.5, its expression being restricted to a population of cardiac fibroblasts and remaining unchanged in the hypomorph at E14.5 ([Figure 6](#fig6){ref-type="fig"}B). However, the two skeletal troponin T genes, Tnni2 and Tnnt3, are located 38 kb upstream and 17 kb downstream, respectively, of the Lsp1-associated NKX2-5-binding region. Furthermore, reduced expression of NKX2-5 expression in the hypomorph heart resulted in upregulation of both troponin genes in the myocardium at E11.5 and E14.5 ([Figure S5](#mmc1){ref-type="supplementary-material"}A; [Figure 6](#fig6){ref-type="fig"}B). That the expression of the two skeletal troponin isoforms was restricted to the atrial myocardium of the developing heart indicates further levels of control that distinguish atrial from ventricular myocardium.

We investigated the putative repressor function of NKX2-5 using short hairpin RNA technology to knock down NKX2-5 expression in the HL-1 cardiac cell line. Cells stably transfected with *shNkx2*-*5* showed a significant decrease in NKX2-5 protein expression ([Figure S5](#mmc1){ref-type="supplementary-material"}B). Using these, we tested the effect of NKX2-5 knockdown on the expression of a luciferase reporter carrying the 461-bp Tnni2-Tnnt3-enh fragment ([Figure 6](#fig6){ref-type="fig"}C). Luciferase activity was significantly enhanced in HL-1 cells deficient for NKX2-5 compared with controls, but unchanged after mutation of the selex DNA-binding site (Tnni2-Tnnt3-enh-mut; [Figure 6](#fig6){ref-type="fig"}C). Furthermore, co-transfection with increasing amounts of an NKX2-5 expression plasmid progressively repressed luciferase reporter activity, but had no effect after mutation of the selex site ([Figure 6](#fig6){ref-type="fig"}D). Together, these results demonstrate the ability of NKX2-5 to repress activity from the Tnni2-Tnnt3-enh enhancer sequence.

Discussion {#sec3}
==========

This study describes the genome occupancy of NKX2-5 during a critical phase of cardiac differentiation in the mouse embryo. Our data show that NKX2-5 binding is an efficient predictor of cardiac enhancer location and even more effective than the binding of P300 at the same stage ([@bib6]).

NKX2-5 Can Bind through an Overlapping Site with MEIS1 In Vivo {#sec3.1}
--------------------------------------------------------------

Our analysis demonstrates that, in vivo, not only is NKX2-5 able to bind to the conventional NKX2-5-binding motif, but it also binds to a related sequence that overlaps with the DNA-binding site for the transcriptional cofactor MEIS1. Comparison of MEIS binding in cardiac precursor tissue of the branchial arches with NKX2-5 in the heart shows that those two factors bind on a common group of enhancers during cardiac differentiation.

A potential role for MEIS proteins as regulators of cardiomyocyte differentiation has been suggested previously ([@bib36; @bib51]). Consistent with this, in the mouse embryo, ablation of MEIS1 results in prenatal death, the null embryos having severe developmental abnormalities ([@bib4; @bib24]), including ventricular septal defects and an overriding aorta ([@bib45]). These are reminiscent of the phenotype found in embryos showing hypomorphic levels of NKX2-5 ([Figure 5](#fig5){ref-type="fig"}A; [@bib40]). Recently, MEIS1 also has been shown to regulate postnatal cardiomyocyte proliferation ([@bib33]). Furthermore, genome-wide association studies have linked both *Nkx2*-*5* and *Meis1* to abnormalities in the PR interval, a region of the electrocardiogram (ECG) that reflects atrial and atrioventricular nodal conduction ([@bib39; @bib44]). Given that defects in conduction are associated with mutations in NKX2-5 in both human and mouse models, our finding that the two factors share a common set of gene targets might account for these results.

We have found that, in the early mouse embryo heart, MEIS1 is co-expressed with NKX2-5 protein in the AHF and the OFT. Levels of MEIS1 are higher in the AHF and decrease through the outflow toward the ventricular myocardium. NKX2-5 shows a reciprocal pattern of early expression, with levels in the myocardium being considerably higher than those found in the AHF.

In a recent study, [@bib3] analyzed the genomic occupancy of MEIS factors in the branchial arches, identifying a very large number (\>60,000) of binding sites. They noted that the top 1% of MEIS-binding regions were associated with genes involved in skeletal muscle development (see [Figure 5](#fig5){ref-type="fig"}F in [@bib3]). Comparison with the NKX2-5-binding data we have obtained now reveals that a significant fraction of NKX2-5-dependent cardiac enhancers harbors an overlapping MEIS site.

The developmental period during which cells migrate from the AHF into the developing heart coincides with a transition from cardiac progenitors to differentiated cardiomyocytes, resulting in many well-documented changes in gene expression ([@bib15; @bib51]) and cell cycling ([@bib11; @bib48]). These coincide with the period over which we identify the switch in expression from MEIS1 to NKX2-5. It is, therefore, tempting to speculate that the subgroup of MEIS1-regulated genes that shows overlapping binding by NKX2-5 is associated with these differentiation changes.

Consistent with this, we found that 79 of the genes associated with those 765 regions are in common with target genes associated with enhancers containing the MEIS1 motif in differentiated cardiac embryonic stem cell ([@bib51]). Furthermore, using previously published data that identifies genes enriched in the AHF compared to the heart and vice versa ([@bib15]), we found that 51 of the genes associated with NKX2-5/MEIS-bound regions are AHF enriched, while 76 are from the heart-enriched class (see [Figure S4](#mmc1){ref-type="supplementary-material"}C). Many of these genes have well-described expression patterns and have been associated with changes in DNA metabolism, cell cycling, and cell signaling (e.g., Tbx20, myocardin, Cdh2, Wnt11, and Wnt2), which are consequent upon cardiac progenitor differentiation. Together, these results suggest that enhancers binding both MEIS1 and NKX2-5 constitute a functionally distinct class of genes compared with those regulated by MEIS1 alone.

Given that early heart growth largely results from the addition of cells from the AHF to the poles of the heart ([@bib10; @bib30]), our data suggest that a significant portion of NKX2-5-binding regions are regulated through successive binding first by MEIS1 and later by NKX2-5 as differentiation (and cardiac morphogenesis) proceeds. Interestingly, a similar temporal pattern of expression of those factors is found during embryonic stem differentiation into beating cardiomyocytes ([@bib51]). In such stem cell cultures, cardiomyocyte precursors express high levels of *Meis1* RNA and relative low levels of the *Nkx2*-*5* transcript. However, when such precursors differentiate into cardiomyocytes, *Meis1* RNA expression decreases and *Nkx2*-*5* RNA expression increases (see [Figure S2](#mmc1){ref-type="supplementary-material"} in [@bib51]).

Transcriptional regulation in a similar manner through shared binding sites and overlapping but distinct spatial patterns of transcription factor expression already has been described during cardiogenesis, from studies of the growth factor FGF10. An *Fgf10* enhancer possesses a shared binding site for NKX2-5 and the transcription factor ISL1. *Fgf10* is activated in the AHF by ISL1, but subsequently repressed by NKX2-5 as cells of the AHF are added to the heart tube ([@bib52]). Our data now suggest a similar regulatory mechanism with MEIS1 and NKX2-5, and we speculate that the presence of overlapping transcription factor binding sites in gene enhancers might therefore be of broader significance during development. For gene enhancers containing such overlapping binding sites, distinct regional patterns of transcription factor expression could combine with cell migration to achieve complex patterns of spatiotemporal regulation.

Common targeting of a set of genes by MEIS1 and NKX2-5 could facilitate several different regulatory mechanisms underlying cardiac differentiation. For example, preferential binding by MEIS1 within the AHF could act to prevent activation of a set of cardiac differentiation genes normally activated by NKX2-5; these genes subsequently would become activated as AHF cells are added to the cardiac tube and MEIS1 is replaced by NKX2-5. An alternative possibility is a role for MEIS1 in activating genes that are part of a cardiac progenitor state program in the AHF. As cardiac precursors integrate into the developing heart, replacement of MEIS1 by NKX2-5 would serve to repress these genes and, thereby, allow cardiomyocyte differentiation. Consistent with this latter model, Nkx2-5 mutants have been reported to show upregulation of progenitor signature genes in the AHF and abnormal persistence of their expression in differentiating myocytes ([@bib40]). Furthermore, our results show that there is a clear difference between biological processes associated with genes showing NKX2-5 binding and those regulated by both NKX2-5 and MEIS. The former are specific to the differentiated cardiac state, whereas the latter are related to other biological processes (metabolism, signaling, and cell-cycle regulation), which perhaps reflects their role in a cardiac progenitor gene program.

A third possibility is suggested by accumulating evidence that gene enhancers can interact with pioneer transcription factors at early stages of development before the target genes are even transcribed ([@bib29]). For example, in the branchial arches, HOXA2 and MEIS binding largely overlaps and it has been suggested that MEIS binding functions to create an accessible platform recognized by HOXA2 ([@bib3]). Similarly, in the mouse embryo trunk, Hox target sequences have been shown to strongly associate with MEIS factors ([@bib38]). Perhaps when both MEIS1 and NKX2-5 activate a common set of enhancers, MEIS1 establishes a ground state that maintains competence for eventual activation by NKX2-5 at the appropriate stage of cardiac differentiation.

Genome-wide studies of NKX2-5-binding sites in the adult mouse heart show no statistically significant enrichment for the de novo binding motif ([@bib49]; data not shown), in contrast to our findings for the E11.5 embryonic heart. This may reflect the exclusive developmental role of the MEIS/NKX2-5 combination, but it also could be accounted for by the nature of ChIP studies themselves. Since no MEIS1 is expressed in the embryonic heart, enhancers containing the de novo binding site will be recovered by ChIP using an NKX2-5 antibody. In contrast, as the adult heart expresses MEIS1, this factor will compete with NKX2-5 for binding onto the de novo motif. Preferential binding by MEIS1 in vivo (comparable with that we detected in vitro) would reduce or abolish recovery of sequences containing the de novo consensus by NKX2-5 ChIP.

NKX2-5 Represses the Muscle Fast Fiber Phenotype {#sec3.2}
------------------------------------------------

NKX2-5 previously has been shown to be capable of acting as a transcriptional repressor ([@bib40]). Our study provides evidence of how widespread such a role may be during development, with nearly 50% of the putative direct targets identified in the embryonic heart likely to be regulated by NKX2-5 in this manner.

Our study of the NKX2-5 hypomorph embryos revealed an unexpected role for NKX2-5 that is notable in several ways. NKX2-5 apparently regulates skeletal muscle fiber type and does so via repression of two skeletal fast isoforms of troponin. Individual isoforms show quantitative differences in the calcium activation of contraction that can affect cardiac muscle performance and heart contraction ([@bib27; @bib37]). The strong upregulation of Tnnt3 and Tnni2 that occurs in the developing atria of the NKX2-5 hypomorph is likely, therefore, to result in alteration of contractile performance, through its impact on myofibrillar calcium activation. The morphological abnormalities seen in the hypomorph hearts at E14.5 included changes (wall thinning and atrial distension) indicative of compromised cardiac function. Our findings indicate that this might not simply be an indirect and cumulative consequence of cardiac dysfunction in the hypomorph; it may in fact be largely driven by a direct impact of reduced NKX2-5 levels on atrial myofibrillar composition. Interestingly, a similar upregulation of fast skeletal troponin isoforms has been observed in several models of cardiac failure induced by loss of either histone deacetylases or the polycomb repressive complex 2 ([@bib14; @bib23; @bib35]).

Experimental Procedures {#sec4}
=======================

Animals {#sec4.1}
-------

All animal work was carried out in accordance with the UK Animals (Scientific Procedures) Act 1986 and with the approval of the MRC National Institute of Medical Research Ethical Review Panel. Genotyping of the transgenic mouse lines *Nkx2*-*5*-*IRES*-*Cre* and *Nkx2*-*5*-*gfp* has been described previously ([@bib40]).

ChIP Assay and Real-Time qPCR Analysis {#sec4.2}
--------------------------------------

Please refer to the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Sequencing and Peak Calling {#sec4.3}
---------------------------

Libraries were prepared with 10 ng immunoprecipitated DNA or input. Samples were sequenced on the Genome Analyzer IIx platform, and ChIP-seq reads were aligned to the mm9 genome assembly using BOWTIE. Peak calling was done using MACS1.4. Please refer to the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for more details.

Sequence and Gene Analysis {#sec4.4}
--------------------------

All enriched GO categories were determined using the programs GeneCoDis3 ([@bib12]) and GREAT for peak-associated genes. De novo motif identification was carried out using 50 bp around the summit of the peak of the top 1,033 regions using MEME-ChIP ([@bib32]). Enhancer coordinates were found in the VISTA Enhancer Browser ([@bib50]) and compared to our set using Galaxy ([@bib20]). For comparison of the different ChIP-seq datasets, 10,000 random sets were generated and compared using pybedtools ([@bib13; @bib41]).

Motif distribution and overlap of the different NKX2-5 motifs among the identified peaks were done with FIMO using default parameters and the matrices identified with MEME.

Expression array data (GEO: [GSE13614](ncbi-geo:GSE13614){#intref0015}) used to analyze working myocardium genes versus atrio-ventricular genes were analyzed using Limma at Geo2r (<http://www.ncbi.nlm.nih.gov/geo/geo2r/>). The p values were adjusted for multiple testing using the Benjamin and Hochberg test, and transcripts were identified as differentially expressed if the adjusted p value was \<0.01.

The region overlap between the NKX2-5 and MEIS dataset was determined using Galaxy ([@bib21]).

RNA-Seq {#sec4.5}
-------

The E11.5 embryonic hearts from the hypomorphic NKX2-5 line were dissected and stored in RNAlater (QIAGEN). After genotyping, three control and three hypomorphic samples were selected for total RNA extraction using Trizol and purified on RNeasy columns (QIAGEN). Total RNA was converted to a library of templates suitable for high-throughput DNA sequencing using the Truseq kit (Illumina). Templates were sequenced using the Illumina Genome Analyzer IIx platform. Sequence reads were aligned to the mm9 genome with TopHat. Mapped reads were analyzed using the Avadis NGS package (Strand Scientific Intelligence; AC test fold change ≥1.5).

EMSA {#sec4.6}
----

Recombinant proteins were synthesized using a coupled transcription-translation system (Promega TnT T7/SP6 kit) and incubated with 0.5 ng radiolabelled oligonucleotide probe in binding buffer (20 mM Tris \[pH 7.6\], 75 mM KCl, 0.25 mg/ml, 1 mM DTT, and 10% glycerol) at room temperature for 10 min. For competition experiments, the excess of unlabelled oligonucleotide probes was added and incubated for 10 min prior to the addition of radiolabelled oligonucleotide probes. Binding reactions were analyzed on 6% 0.5× Tris-borate-EDTA (TBE) polyacrylamide gels electrophoresed at 150 V; gels were dried prior to detection of signal by autoradiography.

In Situ Hybridization {#sec4.7}
---------------------

RNA in situ hybridizations were performed as described previously ([@bib16]). Tnnt3, Tnni2, and Lsp1 RNA probes were synthesized from whole IMAGE clones 3594256, 1448494, and 3488528, respectively.

Immunohistochemistry {#sec4.8}
--------------------

Immunohistochemistry was performed as described previously ([@bib17]) with NKX2-5 (Santa Cruz Biotechnology) and MEIS1 (Abcam, ab19867) antibodies.

High-Resolution Episcopic Microscopy Imaging {#sec4.9}
--------------------------------------------

Embryos were embedded and processed for imaging as described previously ([@bib34]).

Transgenic Fish Experiments {#sec4.10}
---------------------------

Mouse DNA fragments were tested in vivo using the tol2 system ([@bib2; @bib18]). Briefly, 1 kb amplified PCR product flanking the NKX2-5-enriched region was cloned in pCR8/GW/TOPO vector (Invitrogen) and subcloned into pGW_cfosGFP vector. Embryos were scored for GFP heart expression 48 hr after co-injection with Tol2 transposase into one-cell-stage zebrafish embryos.

Transgenic Mouse Experiments {#sec4.11}
----------------------------

The Popdc2 region tested previously in fish was subcloned in an hsp68-LacZ reporter gene. Transient transgenic mouse embryos were generated by the Procedural Services Section at The Francis Crick Institute Mill Hill Laboratory by standard pronuclear microinjection techniques.

Accession Numbers {#app1}
=================

The accession number for the ChIP-seq and RNA-seq data reported in this paper is GEO: [GSE44576](ncbi-geo:GSE44576){#intref0025}.
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![ChIP-Seq Dataset Analysis\
(A) Top selected GO terms for biological processes associated with the 3,313 genes identified are shown.\
(B) Regions enriched for either NKX2-5 or P300 that have been tested in vivo are plotted according to their ability to drive cardiac expression. Actives or negatives in heart represent the percentage of enhancers able or not able to drive cardiac expression of the β-galactosidase reporter gene (p \< 0.0007 according to two-tailed Fisher's exact test).\
(C) De novo motif discovery using ChIP-MEME identified two in vivo NKX2-5-binding motifs (called selex and de novo). Selex and de novo match the UniProbe consensus motif for NKX2-5 and MEIS1, respectively. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![NKX2-5 and MEIS1 Expression Pattern\
(A) *Nkx2*-*5* and *Meis1* whole-mount in situ hybridization in E8.5 and E9.5 mouse embryos shows their co-expression in the anterior heart field (AHF, white arrows) and outflow tract (OFT, arrowheads).\
(B) NKX2-5 and MEIS1 immunohistochemistry on an E8.5 mouse embryo (transversal section) showing colocalization in the distal OFT (bracket in merge). Level of section is shown with a white line in (A). AHF and heart tube (HT) are depicted in the MEIS1 immunostaining.](gr2){#fig2}

![NKX2-5 and MEIS1 Bind on the Same DNA Motif\
(A) Electrophoretic mobility shift assay (EMSA) showing that NKX2-5 and MEIS1 bind the de novo probe (black arrowheads). Note the specific competition when an unlabelled competitor (de novo-c) is used. White arrowheads indicate supershift when a specific antibody against the protein tested is used. Note that competition with a mutated unlabelled probe is observed with de novo m2, but not de novo m1, when NKX2-5 protein is used. Competition with a mutated unlabelled probe is observed with de novo m1, but not m2, when MEIS1 protein is used.\
(B) The selex unlabelled probe is a better competitor than the de novo unlabelled probe when used with selex or de novo radioactive probes. Black arrowhead indicates NKX2-5 probe complex.\
(C) EMSA showing the absence of any supershift when both NKX2-5 and MEIS1 proteins are added in increasing amounts. Increasingly prominent band slightly above the position of the MEIS1 complex in lanes 10 and 11 (indicated with ^∗^) is detectable in the presence of MEIS1 alone in lane 3, and its apparent increase simply reflects the increase in overall MEIS1 concentration in the titration experiment. Black arrow and black arrowhead indicate MEIS1 and NKX2-5 binding on the de novo probe, respectively. Note the disappearance of NKX2-5 binding in lanes 10 and 11 at higher concentrations of MEIS1 (red arrow).\
(D) NKX2-5 and MEIS1 activate the de novo fragment cloned in pGL3 in 3T3 cells. Note the absence of synergistic activation. The graph shows relative luciferase reporter activity normalized to reporter construct alone. Average of three independent experiments is shown. Error bars represent the SEM.](gr3){#fig3}

![NKX2-5 and MEIS1 Successively Bind a Popdc2 Enhancer\
(A) ChIP-seq trace at the Popdc2 locus for the two experiments carried out (s1 and s4). Black bar indicates the region found enriched for NKX2-5 binding and tested in transgenic mice (see below).\
(B) Representative image of a mouse transgenic embryo at E9.5 showing that the Popdc2 enhancer is reproducing endogenous Popdc2 gene expression in the heart and AHF. Four independent embryos expressed the reporter gene of the seven PCR-positive embryos for the transgene. Planes a and b represent transversal sections as indicated on the whole mount. Asterisk shows pharyngeal arches, white arrow in plane b shows proepicardium, and white arrowhead indicates expression of the transgene in the AHF.\
(C) ChIP analysis carried out with chromatin purified from E9.5 AHF and heart with either MEIS1 or NKX2-5 antibodies. Representative results of qPCR analysis with primers against the region of the Popdc2 promoter enriched for NKX2-5 binding are shown. Relative enrichment is presented over a negative control region in the gamma-crystallin gene (gcrys). ^∗^p \< 0.05, ^∗∗^p \< 0.001 according to a two-tailed Student's t test.\
(D) Venn diagram depicting the overlap between NKX2-5- and MEIS-enriched regions. In red are the number of those overlapping regions corresponding to the overlapping binding site.\
(E) Top selected GO terms were identified with GREAT for biological processes associated with the genes associated with either the NKX2-5- or NKX2-5/MEIS-bound regions.](gr4){#fig4}

![NKX2-5 Acts as an Activator and a Repressor\
(A) Four-chambered view comparing hearts from hypomorphic embryos to controls using high-resolution episcopic microscopy. At E11.5, no obvious morphological defect can be detected. At E14.5, hearts from hypomorphic embryos present ventricular septal defect (star) and thinning of the compact layer ventricular free wall (compare red size bar).\
(B) Venn diagram depicts the overlap between NKX2-5-enriched region-associated genes (white) and genes downregulated (gray) and upregulated (red) in the heart of hypomorphic embryo.\
(C) Most enriched biological processes in the direct target genes list are shown.\
(D) Direct targets are categorized by expression pattern as AVC specific or working myocardium. n.s., non-significant; ^∗∗^p \< 0.002, ^∗^p \< 0.0489 according to two-tailed Fisher's exact test. See also [Figure S4](#mmc1){ref-type="supplementary-material"}D.](gr5){#fig5}

![NKX2-5 Represses Cardiac Expression of Fast Troponin Isoforms\
(A) ChIP-seq trace at the repressed Lsp1 locus for the two experiments carried out (s1 and s4). Black bars indicate regions found enriched for NKX2-5.\
(B) In situ hybridization on sections of E14.5 control and hypomorph hearts, using probes for Tnni2, Tnnt3, and Lsp1. Note the upregulation of Tnni2 and Tnnt3 signals in the hypomorph atria (black arrows). See also [Figure S5](#mmc1){ref-type="supplementary-material"}A.\
(C) Tnni2-Tnnt3 enhancer (Tnni2-Tnnt3-enh) activity in control and NKX2-5-deficient HL-1 cells is shown.\
(D) Co-transfection of Tnni2-Tnnt3-enh with an increasing quantity of *Nkx2*-*5*-expressing vector shows a decrease of reporter activity. Tnni2-Tnnt3-enh-mut reporter vector is unaffected by *Nkx2*-*5* overexpression in HL-1 cells. Only significant changes are indicated. ^∗^p \< 0.05 according to a two-tailed Student's t test.](gr6){#fig6}
